AstraZeneca PLC (LON:AZN) target bumped up to 4,900.00GBX, released a ratings update earlier today by Cantor Fitzgerald
- Updated: February 11, 2017
Cantor Fitzgerald bumped up the target of AstraZeneca PLC (LON:AZN) to 4,900.00GBX stating a potential upside of 0.10%.
On 02/08/2017, Exane BNP Paribas released a statement for AstraZeneca PLC (LON:AZN) maintained the target price at 5,300.00GBX that suggested an upside of 0.20%.
Having a price of 4,460.00GBX, AstraZeneca PLC (LON:AZN) traded 1.13% higher on the day. The last close is down -0.85% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time period. AZN has recorded a 50-day moving average of 4,429.89GBX and a 200-day moving average of 4,666.07GBX. 3,934,506 shares of the stock were exchanged, up from an average trading volume of 3,079,530
See Chart Below
AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a P/E ratio of 16.76 The company’s market cap is currently 0 GBX.
In addition to Cantor Fitzgerald reporting its target price, a total of 29 firms have reported on the stock. The consensus target price is 61.96GBX with 4 firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 1 firm rating the stock a sell.
About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.